AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication [Yahoo! Finance]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
Tagrisso is indicated for patients with exon 19 deletions or exon 21 (L858R) mutations. Tagrisso is AstraZeneca's top-selling cancer drug, and in the second quarter of 2024, it generated around $1.6 billion in sales The approval follows the FDA's Priority Review based on results from the LAURA Phase 3 trial. Tagrisso reduced the risk of disease progression or death by 84% compared to placebo. Median progression-free survival (PFS) was 39.1 months in patients treated with Tagrisso versus 5.6 months for placebo. Overall survival (OS) results remain immature at this current analysis. The trial continues to assess OS as a secondary endpoint. Each year in the US, there are more than 200,000 people diagnosed with lung cancer, and 80-85% of these patients are diagnosed with NSCLC, the most common form of lung cancer. Approximately 15% of NSCLC patients in the US have EGFR mutations. Nearly one in five people diagnosed with NSCLC has an unresectable tumor. The safety and tole
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- US' first self-administered flu vaccine could increase accessibility and uptake [Yahoo! Finance]Yahoo! Finance
- AstraZeneca's Tagrisso gains FDA approval for stage III NSCLC [Yahoo! Finance]Yahoo! Finance
- AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy? [Yahoo! Finance]Yahoo! Finance
- AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC [Yahoo! Finance]Yahoo! Finance
- Qure.ai secures $65m in Series B financing to expand into US and other markets [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 9/26/24 - Form 6-K
- 9/23/24 - Form 6-K
- 9/23/24 - Form 6-K
- AZN's page on the SEC website